R R

What Is Promacta?

Promacta is a prescription medication containing eltrombopag, a thrombopoietin receptor agonist. It helps increase platelet production in patients with certain blood disorders associated with low platelet counts. Promacta is approved for selected cases of persistent or chronic immune thrombocytopenia, hepatitis C-associated thrombocytopenia, and severe aplastic anemia. It is available in oral formulations with administration requirements involving food and mineral-containing products. Treatment requires regular blood counts and liver function monitoring because excessive platelet increases and serious liver complications can occur.

Link to This Resource Page

Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.

To display this...

What Is Promacta?

Promacta is a prescription medication containing eltrombopag, a thrombopoietin receptor agonist. It helps increase platelet production in patients with certain blood disorders associated with low platelet counts. Promacta is approved for selected cases of persistent or chronic immune thrombocytopenia, hepatitis C-associated thrombocytopenia, and severe aplastic anemia. It is available in oral formulations with administration requirements involving food and mineral-containing products. Treatment requires regular blood counts and liver function monitoring because excessive platelet increases and serious liver complications can occur.

read more about promacta ...

Copy this HTML:

Copy HTML Copied!

How Does Promacta Work?

Promacta stimulates the thrombopoietin receptor on bone marrow cells involved in platelet production. Activating this receptor encourages the growth and maturation of megakaryocytes, which release platelets into the bloodstream. Increasing platelet counts can reduce bleeding risk in certain patients with thrombocytopenia. In severe aplastic anemia, eltrombopag can also support blood cell production in selected treatment settings. Promacta does not directly replace platelets or treat every cause of low platelet counts. Its use depends on the underlying diagnosis and response to treatment.

What Conditions Does Promacta Treat?

Promacta is approved for persistent or chronic immune thrombocytopenia in adults and children aged one year and older who have had an insufficient response to other treatments. It is also approved for thrombocytopenia in patients with chronic hepatitis C who need interferon-based therapy, under specific conditions. For severe aplastic anemia, Promacta is used with standard immunosuppressive treatment in eligible patients aged two years and older or as treatment for refractory disease in specified patients. It should not be used simply to normalize platelet counts. Eligibility depends on diagnosis, age, liver function, previous treatment, and bleeding risk.

How Should Promacta Be Taken?

Promacta is taken orally, generally once daily, with the dose determined by the indication, age, liver function, and platelet response. For persistent or chronic immune thrombocytopenia, adults commonly begin at 50 mg once daily, although some patients require a lower starting dose. Severe aplastic anemia has separate regimens that may involve higher doses. Promacta should be taken without a meal or with a meal containing no more than 50 mg of calcium. It should be separated from antacids, dairy products, mineral supplements, and other polyvalent cations by at least two hours before or four hours after administration. Regular blood testing guides dose adjustments.

What Are the Side Effects and Warnings of Promacta?

Common adverse effects include nausea, diarrhea, headache, fatigue, and changes in liver laboratory tests. Promacta carries a boxed warning for hepatic decompensation in patients with chronic hepatitis C receiving interferon and ribavirin and for hepatotoxicity. Other serious risks include blood clots, excessive platelet increases, and possible cataract development or progression. Clinicians monitor platelet counts and liver function during treatment. Patients should report jaundice, dark urine, severe abdominal discomfort, sudden neurological symptoms, leg swelling, or new vision changes. Treatment may need to be adjusted or discontinued when serious adverse effects develop.

Common Questions About Promacta

Is Promacta the same as eltrombopag?

Yes. Promacta is the brand name for eltrombopag, a thrombopoietin receptor agonist that helps increase platelet production.

Can Promacta treat low platelet counts?

Yes. Promacta is approved for specific conditions associated with thrombocytopenia, including selected cases of immune thrombocytopenia and severe aplastic anemia.

Can Promacta be taken with dairy products?

Promacta should be separated from calcium-rich foods, including dairy products, according to its administration instructions. Calcium can reduce eltrombopag absorption.

Can Promacta affect the liver?

Yes. Promacta can cause liver injury and carries boxed warnings involving hepatotoxicity and hepatic decompensation in certain hepatitis C treatment settings.

References

Eltrombopag. MedlinePlus. https://medlineplus.gov/druginfo/meds/a609011.html. Date Accessed November 2, 2026.

Eltrombopag. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Eltrombopag. Date Accessed November 2, 2026.

PROMACTA (eltrombopag) Prescribing Information. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022291Orig1s040lbl.pdf. Date Accessed November 2, 2026.

Revolade (eltrombopag). European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/revolade. Date Accessed November 2, 2026.

Thrombopoietin Receptor Agonists. LiverTox. https://www.ncbi.nlm.nih.gov/books/NBK548101/. Date Accessed November 2, 2026.